Updated: AstraZeneca foresees blockbuster sales for Claudin 18.2 ADC, but Ultomiris flops in rare disease

July 27, 2026 07:03 AM EDT R&DPharma As­traZeneca’s pipeline strug­gles con­tin­ue as it re­ports dis­ap­point­ing da­ta in can­cer, rare dis­ease Ayisha Sharma News Reporter As­traZeneca said Mon­day that two key late-stage tri­als yield­ed sub­par re­sults — one test­ing an an­ti­body-drug con­ju­gate in stom­ach can­cer and the oth­er eval­u­at­ing Ul­tomiris in … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER